Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASH 2018 /
New therapies for transfusion dependent MDS patients

1st - 4th Dec 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 02.12.18
Views: 507

Dr Alan List - Moffitt Cancer Centre, Tampa, USA

Dr Alan List speaks to ecancer at ASH 2018 about new therapies for transfusion dependent myelodysplastic syndrome (MDS) patients.

He explains that treatments for lower risk MDS patients with anaemia have a short duration of response, therefore there is a need for more effective treatments. One of these is luspatercept, an erythroid maturation agent.

Dr List discusses the results of the Phase III MEDALIST trial, concluding that the use of luspatercept was very durable and that the vast majority of patients had clinical benefits.

Watch Dr List's press conference here

Read the article about this work here.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation